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Introduction
Bilirubin encephalopathy (BE) is an important cause of cerebral palsy, developmental
delay and hearing impairment particularly in low-middle-income countries (LMICs).1,2
The actual incidence of BE is difficult to estimate in both high-income countries and
LMICs. In LMICs, this is largely due to delayed diagnosis, non-recognition in ICD coding, under-reporting or even lack of organized data collection and reporting in LMICs.2
Interventions such as universal neonatal jaundice risk assessment and screening, coupled
with the wide availability of treatment modalities such as Rhesus immunoglobulin (Rhogam™) and intensive phototherapy resulted in the apparent near elimination of kernicterus
in many countries, as reported in a survey done in the USA between 1980 and 19963 and
one done in Denmark during a similar time period.4 This was followed by an apparent
re-emergence of kernicterus spectrum disorder (KSD) following a shift to early (<48
hours) hospital discharge after delivery and lack of monitoring of hyperbilirubinemia at
home.5 More recent scrutiny of data proposed that the reported disappearance of KSD
was most likely merely a period of underreporting.6 Limited data from two high-income
countries (Canada and Denmark) reported kernicterus at a rate of 1 in 44,000 live births
and 0.6 per 100,000 live births, respectively,7,8 while the Parents of Infants and Children
with Kernicterus report 650–750 children with kernicterus in their network mostly from
the USA and the UK (Personal Communication Susan Haas). Nonetheless despite these
cases, KSD is generally rare in high-income countries with most doctors never seeing a case
throughout their years of practice. The same cannot be said of the LMICs, especially Sub33
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Abstract: Acute bilirubin encephalopathy (ABE) remains a significant cause of morbidity and
mortality throughout the world, especially in low-middle-income countries where it can account
for up to 15% of neonatal death. The pathophysiology of this acute life-threatening event of
infancy and its potential evolution to kernicterus remain poorly understood. In this review, we
start by reviewing the terminology of hyperbilirubinemia and its clinical consequences, ABE
and later kernicterus spectrum disorder (KSD). We then review the pathogenesis of ABE and
discuss clinical factors that can contribute to its pathogenicity. We examine in detail the clinical
correlates of ABE and KSD. We present a comprehensive approach to its diagnosis and conclude
with a set of simple clinical interventions ranging between primary preventive and rehabilitative
measures that may help reduce the incidence of this largely preventable disease.
Keywords: acute bilirubin encephalopathy, neonatal jaundice, kernicterus, kernicterus spectrum
disorder, low-middle-income countries
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Saharan Africa and South-East Asia that bear the main burden
of KSD, a reflection of weak health care systems amidst a high
proportion of population expressing the glucose-6-phosphate
dehydrogenase (G6PD) deficiency gene.9–11 In tertiary settings
in Nigeria, acute bilirubin encephalopathy (ABE) accounts
for 3.4% of neonatal admissions with 21.4% of those infants
dying12 and at least 15% of neonatal deaths.
This review focuses on the mechanisms of neurologic
injury in ABE, risk factors for neuronal injury, clinical
correlates of ABE and KSD, disease progression as well as
diagnosis and briefly discusses prevention.

Defining terms
The term kernicterus finds its roots in the German word
“kern” for nucleus and the Greek word “ikteros” for jaundice. Originally it was used by Christian Georg Schmorl to
connote the pathologic yellow staining of the basal ganglia
and cerebellum.13 However, over time, the term was adopted
to refer to both acute and chronic BE. In 2004, the AAP in
an attempt to clarify the use of terminologies recommended
that the term ABE be used to describe acute bilirubin neurological symptoms manifesting in the first few weeks of
life, while kernicterus should be reserved to describe the
more chronic sequelae of ABE.14 Despite these suggestions, there continued to be considerable term confusion,
prompting Le Pichon et al15 to suggest the continued use
of ABE for acute manifestations of BE while replacing all
previously used terms for chronic BE (including but not
limited to kernicterus, bilirubin-induced neurologic dysfunction [BIND], subtle kernicterus, etc.) with the term KSD.
Like all spectrum disorders, KSD ranges from less severe
symptoms to very severe manifestation. At the milder end
of the spectrum, children may have movement disorders,
isolated hearing loss and/or auditory dysfunction including
isolated auditory neuropathy.16,17 Those children with more
severe manifestations will have a permanent incapacitating
condition characterized by dystonia, choreoathetosis, severe
neurologic hearing impairment, paralysis of upward gaze and
dental enamel dysplasia.18,19

Pathogenesis of ABE
Neuroanatomy of BE

Post-mortem and animal studies have shown that BE results
from neural damage of typical brain regions, namely: 1)
globus pallidus, 2) sub-thalamic nuclei, 3) hippocampus
4) oculomotor nuclei, 5) ventral cochlear nuclei and 6) the
Purkinje cells and dentate nuclei of the cerebellum.20 This is
usually seen as yellow staining of these regions with evidence
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of neuronal damage.20 There are considerations that regional
damage of parts of the auditory or extrapyramidal pathways
may be more severe in some areas as compared to other areas
and may occur in isolation, sparing other common regions
of the brainstem.21 It is also noteworthy that KSD typically
spares the cortex and, interestingly, the striatum and thalamus.
This is noteworthy as many of these structures share the same
blood supply as areas that are sensitive to hyperbilirubinemia,
highlighting that there must be an underlying genetic or biochemical mechanism to explain the selective susceptibility
of these regions to hyperbilirubinemia.
Magnetic resonance imaging (MRI) findings consistent
with KSD include bilateral, symmetric, high-intensity signals
in the globus pallidus and sub-thalamic nuclei. During the
phase of ABE, the increased signal is most obvious on the T1
sequences. However, as KSD develops, the MRI abnormalities will become more obvious on T2 sequences22 (Figure 1).

Mechanism of bilirubin-induced neurotoxicity
The mechanism of bilirubin-induced neuronal damage is not
completely understood and appears to have several pathways
including bilirubin-induced lipid peroxidation, neuroinflammation, excitotoxicity as well as sustained energy failure24
(Figure 2).
High levels of unbound (free) bilirubin in the brain have
been suggested to be immune-stimulatory.25 Activation of
microglial cells has been demonstrated in vivo leading to
upregulation of pro-inflammatory cytokines such as tumor
necrosis factor-α and interleukins (IL) 1β and 6 with subsequent inflammation and necrosis of the affected cells24–26
(Figure 2). This may also explain why conditions associated with systemic inflammation, such as sepsis, potentiate
bilirubin-induced neuronal injury.
This line of reasoning is supported by evidence from
Gunn rat experiments. Gunn rats lack the functional UDP
glucuronosyltransferase enzyme, UGT1A1.27 In humans,
deficiency of this enzyme causes Crigler-Najjar and Gilbert
syndrome. Crigler-Najjar syndrome is a rare autosomal
recessive disorder with severe (type I) and less severe
(type II) congenital non-hemolytic jaundice and deficiency
of UGT1A1. Gilbert syndrome is the most common inherited disorder of bilirubin glucuronidation due to mutations
in the promoter region of the UGT1A1 leading to mild,
usually asymptomatic unconjugated hyperbilirubinemia
from reduced production of UGT1A1.28 Aside from being
jaundiced, the Gunn rats are otherwise normal at birth, and
most have lifelong mild to moderate hyperbilirubinemia with
mild to moderate neurological signs. In a commonly used
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Figure 1 T2-weighted axial MRI at 6 months of age in a male born at 40 weeks of gestation with hyperbilirubinemia due to G6PD deficiency and a total bilirubin of 39 mg/dl
(665 µM) at 125 hours of age, treated with two double-volume exchange transfusions, diagnosed at 27 months of age with moderate to severe, motor-predominant
kernicterus.15,23
Notes: The hyperintensity of the globus pallidus bilaterally (left panel, arrows). In the right panel, the abnormal hyperintensity is shown in 5 continuous 3 mm axial T2 slices
from rostral to caudal (a–e), with the globus pallidus on the right of the figure outlined with a dotted line. Panel c (dotted line and arrow) is extracted from the image shown
in the left panel, and the bottom panel (e) is below the globus pallidus and not outlined because there is no abnormal hyperintensity.
Abbreviations: G6PD, glucose-6-phosphate dehydrogenase; MRI, magnetic resonance imaging.

experimental model, Gunn rats are injected with a sulfonamide that competitively displaces bilirubin from albumin,
and the resultant free bilirubin diffuses into the brain and
causes ABE. In this animal model, there is strong evidence
that supports chronic microglial activation leading to chronic
neuroinflammation.29,30 This evidence further sheds light
on the possibility of continued neuronal damage after the
acute phase of BE and the possible extension of the window
of opportunity for therapeutic interventions beyond the 1st
week of life. Opportunities for intervention include targeting
chronic neuroinflammation for an extended period of time
following the acute injury; although to date there have been
no clinical trials in humans or animals targeting this potential
mechanism of action. Other opportunities might conceivably include specific therapies designed to promote more
beneficial neurodevelopment, medications targeting neuronal
hyperexcitability to suppress dysfunctional neuronal activity
and transplantation of neural progenitor cells (stem cells) to
replace specific subpopulations of neurons and hopefully to
re-connect and re-establish beneficial function. It is important to note that all these possible therapeutic interventions
beyond the 1st week are at present purely speculative.
Glutamate and N-methyl-D-aspartate (NMDA) receptor
subtype is also thought to contribute to bilirubin-induced
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neuronal injury (Figure 2). It is known that there is a time
course-dependent overexpression of NMDA receptors in
the neonatal striatum (including the globus pallidus), the
hippocampus, and the Purkinje cells.31 This temporal elevation of the glutamate receptors in the globus pallidus may
set the stage for a glutamate driven excitotoxicity model in
the immature brain.32 The excitotoxicity model proposes that
excessive glutamate receptor activation ultimately results in
cell death. Glutamate binds to both NMDA and non-NMDA
(α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
and kainate) receptors. Both types of receptors, when activated, allow influx of cations into the cells. NMDA receptors have a high permeability to calcium, but under normal
circumstances are modulated by Mg2+, preventing the channel from opening. Exposure to bilirubin has been shown
to affect several mechanisms affecting ionic equilibrium.
Bilirubin reduces oxidative phosphorylation in the mitochondria. Under normal circumstances, ATPase-dependent
ion pumps maintain homeostasis by pumping cations out
of the cell. However, prolonged activation of the glutamate
receptors results in mitochondrial failure (ATP depletion).
With prolonged mitochondrial failure, the ATP-dependent
ion pumps fail leading to prolonged depolarization. The
depolarization in turn causes Mg2+ to dissociate from the
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Figure 2 Schematic overview of the proposed pathophysiological mechanisms underlying bilirubin-induced neuronal injury.
Notes: Unconjugated hyperbilirubinemia exerts direct effects on the plasma membranes, mitochondria and/or endoplasmic reticulum leading to excitotoxicity, mitochondrial
energy failure and increased intracellular calcium levels. Increased intracellular calcium alters enzyme activities and affects mitochondrial function. Together these mechanisms
activate directly or indirectly apoptotic and or necrotic cell death. If unconjugated bilirubin exposure is of a sufficient degree and/or duration, then irreversible neuronal
damage ensues. Sites of action of bilirubin are denoted by the yellow haze surrounding the area.
Abbreviations: AMPAR, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; EAAT, excitatory amino acid transporter; IL, interleukin; KainateR, kainate
receptor; NMDAR, N-methyl-D-aspartate receptor; TNF, tumor necrosis factor.

NMDA receptors (a voltage-dependent process). This in turn
leads to increased Ca2+ influx. Bilirubin is also believed to
affect excitatory amino acid transporters, including glutamate
transporters, resulting in prolonged exposure of glutamate in
the synaptic cleft. This in turn activates the glutamate receptors, both NMDA and non-NMDA receptors. Furthermore,
bilirubin in the brain contributes to oxidative stress by lipid
peroxidation of membranes of the endoplasmic reticulum.
In Gunn rats, bilirubin-induced neurotoxicity (including
auditory brainstem response [ABR] abnormalities) was
prevented by competitively inhibiting lipid peroxidation with
minocycline.33,34 This mechanism is not well understood as
other antioxidants (12-pyrazolinominocycline and tauroursodeoxycholic acid)35 with similar potency as bilirubin were
found to also inhibit lipid peroxidation but do not prevent
neuronal injury. Ultimately, these mechanisms contribute to a
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massive Ca2+ influx. This in turn causes edema and activation
of the final common pathways for apoptosis and necrosis.28,29

Risk factors for BE
Total serum bilirubin (TSB) levels have been used in the
management guidelines of neonates with hyperbilirubinemia to define critical values for interventions such as phototherapy and exchange blood transfusion. TSB measures
both conjugated and unconjugated bilirubin in the blood.
The unconjugated bilirubin is largely bound to albumin but
a small proportion remains as free or unbound bilirubin.
High TSB levels have been associated with a risk of BE
in a dose-dependent pattern since at least the 1950s.36 This
stems largely from the understanding that high TSB levels
correlate with high free unbound unconjugated bilirubin
levels at the membrane surfaces as a result of saturating the
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albumin binding sites. Free bilirubin is available to permeate
membranes, including brain cells, and cause neuronal injury.
However, reports of ABE at TSB levels considered to be nonhazardous, that is, below critical values for exchange blood
transfusion (low bilirubin KSD) have highlighted the need to
establish a critical value of TSB below which BE is unlikely
to occur.37 Low bilirubin ABE is possible in the context of
hypoalbuminemia or impaired albumin binding.38 Bilirubin
is transported bound to albumin in a largely predictable way.
Bilirubin bound to albumin is water soluble and does not
cross the blood–brain barrier (BBB). Albumin has two types
of binding sites for bilirubin – a high affinity site and other
lower affinity sites. Bilirubin binding to albumin saturates
when the molar ratio of bilirubin to albumin exceeds 1:1 at a
pH of 7.2 and a temperature 37.5°C. Unbound (free) bilirubin
is expected to be a more appropriate measure of the risk for
BE than TSB. However, it is currently not practical to assay
UB in clinical settings. Bilirubin:albumin (B:A) molar ratio,
on the other hand, is easily assayed and has previously been
proposed as a surrogate for UB and, consequently, CNS exposure to bilirubin. A threshold for commencement of treatment
using B:A molar ratio was recommended;39 however, in the
clinical setting, it has not been proved to be superior to TSB
estimation alone in predicting neurotoxicity.39,40
Immaturity of the brain cells (especially in preterm
infants) also increases susceptibility to neuronal damage
even at lower bilirubin levels.41 This observation has been
confirmed in animal models as well.42 Mechanisms for this
increased susceptibility in the preterm include age-dependent
ability of brain cells to metabolize bilirubin and lower expression levels of P-glycoprotein (6-GP).43,44 6-GP, also referred
to as multidrug resistance-associated protein 1, is an ATPase
membrane efflux pump present in the BBB that serves to
maintain a brain–blood bilirubin gradient (about 1–2% of
serum bilirubin concentration), thereby protecting the brain
from excess levels of bilirubin.43,44 6-GP has a high affinity
for bilirubin when compared to other substrates like leukotrienes (about 10 times higher).45 Some authors believe that
its expression is lower in the brainstem auditory structures
accounting at least in part for this region’s high susceptibility
to bilirubin-induced neurotoxicity.
Acidosis also increases bilirubin neurotoxicity.26 Vázquez
et al demonstrated that acidosis increases hydrophobic inclusion of bilirubin into erythrocyte membranes rather than
aggregation of bilirubin on the surface of membranes from
albumin dissociation and proposed the same mechanism in
the pathogenesis of neurotoxicity with acidosis.46
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Other potentiating neurotoxic factors include sepsis, drugs
or other binding competitors, hypercarbia, hyperosmolality,
hypoxia, asphyxia and hemolysis.26,47 Sepsis increase susceptibility to ABE by increasing blood–brain permeability and
decreasing the albumin binding capacity.47 Park et al, while
comparing the response of preterm neonates with or without
sepsis to lipid infusion, observed poor utilization of infused
fats in the sepsis group.48 Plasma free fatty acid concentration, which is known to displace bilirubin from albumin, is
increased in sepsis. Hansen et al, however, concluded that the
evidence in support of ABE susceptibility with sepsis was
weak. They came to this conclusion on the basis of a study
that demonstrated that sepsis did not increase brain mitochondrial oxidation of bilirubin, the hypothesized mechanism of
bilirubin-induced neuronal injury in this context.49
In the 1950s, the wide use of sulfonamides for infection
prophylaxis in neonates was associated with KSD.50 This was
due to displacement of bilirubin from its binding site with
albumin by sulfonamides. Several other drugs have been
associated with similar displacement of bilirubin.50
Hypercarbia increases brain blood flow with resultant
increase in entry of bilirubin into the brain.51 Hyperosmolality (as seen in hyperglycemia, hypernatremia and azotemia),
hypoxia and asphyxia affect the integrity of the BBB leading
to prolonged exposure of the brain to bilirubin (Figure 3).
Hemolysis increases the risk of BE mainly due to the
rapid increase in bilirubin production, most notably in the
context of delayed treatment.52 During rapid hemolysis, TSB
levels may rise more quickly than it can be conjugated or
isomerized following transport into the skin53 leading to
neuronal injury. This rapid elevation of TSB results in a proportional elevation of free bilirubin (as bilirubin binding to
albumin follows Michaelis–Menten kinetics). Consequently,
the brain is exposed to higher levels of free bilirubin resulting
in increased risk for BE. G6PD deficiency is one of the most
common causes of non-immune hemolytic jaundice. Eleven
million neonates delivered each year are G6PD deficient
globally.2 Studies from Nigeria, Oman, Singapore and the
USA have demonstrated at least a fourfold increase in the
incidence of KSD in G6PD-deficient neonates compared to
non-G6PD-deficient neonates.3,9,10,54,55 As stated by Kaplan
and Hammerman, this increased sensitivity observed in
infants with G6PD is likely a result of a combination of factors, including excessive bilirubin production, diminished
conjugation and other genetic and environmental pressures.56
More recently, Hegyi et al showed that increasing doses
of intra-lipids in infants born preterm had a direct effect on
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Figure 3 Schematic of factors contributing to bilirubin-albumin hemodynamic.
Abbreviations: ABOi, ABO incompatibility; B+A complex, bilirubin:albumin complex; BBB, blood–brain barrier; BE, bilirubin encephalopathy; G6PD def, glucose-6phosphate dehydrogenase deficiency; MRP-1, multidrug resistant protein-1; Rhi, Rh (Rhesus) blood group incompatibility.

the free bilirubin concentration.57 Presumably, this occurs
as with increasing concentration of intra-lipids, free fatty
acids, known to competitively compete with the bilirubin
albumin binding site, displace bilirubin. This is especially
noteworthy that at higher doses of free fatty acids, the free
bilirubin concentration no longer follows a linear relationship to the total bilirubin. It follows that the total bilirubin
concentration probably underestimates the free bilirubin and
consequently the risk for BE.
Many unanswered questions in the pathogenesis of ABE
remain. For example, it is not clear why some term and nearterm neonates with extreme hyperbilirubinemia (500–600
µmoles/l or 30–35 mg/dl) escape unharmed, while other
neonates develop KSD even at total bilirubin levels below
exchange transfusion threshold.58 This opens the possibility
that there may be other genetic factors at play that predispose
certain neonates and protect others from unbound bilirubin.

categorized into 3 phases with variable times of onset for
each phase.60 Phase 1 (early ABE) manifests early usually
at 3–5 days of life with decreased alertness, poor feeding,
hypotonia and weak Moro. Phase 2 (intermediate ABE)
has variable onset and duration, usually presenting in latter in the 1st week but can be latter with stupor, irritability,
hypertonia of extensor muscles, which may alternate with
hypotonia, opisthotonos, retrocollis and high-pitched cry.
Phase 3 (advanced ABE) often presents after the 1st week
and is typically characterized by hypotonia. Other features
include coma, pronator spasm of upper extremities, sun setting eyes, fever, inability to feed and apnea.53,56 Mortality
may be at least as high as 21%,12 usually due to respiratory
failure or refractory seizures.
The clinical features of encephalopathy in preterm neonates are the same as term neonates albeit more subtle, mainly
due to neuronal immaturity and masking clinical conditions.61

Clinical correlates

KSD

The signs and symptoms of ABE may be subtle requiring a
high index of suspicion, or apparent with overt neurologic
abnormalities.59 The spectrum of manifestation has been

KSD is a more chronic and permanent clinical sequel of
bilirubin toxicity in neonates who survive ABE. It evolves
slowly over several years in the affected children.62 In the
early phase, which occurs in the 1st year of life, it usually

ABE
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presents with hypotonia, hyper-reflexia, persistence of tonic
neck reflex and delayed milestones.62 After the 1st year, the
manifestation is more variable, with a tetrad of symptoms
including auditory, visual and dental abnormalities, and
extrapyramidal disturbances. Auditory abnormalities usually
present as a neural hearing loss, often mischaracterized as
sensorineural hearing loss (SNHL), but best characterized
by auditory neuropathy spectrum disorder (ANSD), since
the auditory dysfunction is localized to auditory brainstem
nuclei ± possibly the auditory nerve, with no evidence of a
primary sensory (i.e., hair cell) involvement. This is one of
the earliest features of ABE and KSDs and it may be seen
even in the absence of other clinical manifestations of BE.18
Visual abnormalities include paralyses of upward gaze, horizontal gaze dysfunction and a blank stare or “scared appearance” caused by the combination of upward gaze paresis and
facial dystonia.63 Dental abnormalities include dental enamel
hypoplasia of the deciduous (baby) teeth and green stained
teeth. Extrapyramidal disturbances consist of dystonia, the
commonest manifestation, and athetosis, although chorea
may also occur. Bulbar functions may also be impacted.62,64
The cognitive function of individuals with KSD is relatively
speared.11 Some studies suggest otherwise;58 however, it is
likely that these studies underestimate the cognitive abilities
of the affected subjects due to the significant motor limitations they suffer from.

Diagnosis
In the past, it was erroneously believed that the diagnosis of
BE could only be made by autopsy. Using history, a focused
physical examination, the BIND score,16,54 and electrophysiological and neuroimaging studies, the diagnosis can be
ascertained with reasonable certainty. Assessment of the
encephalopathy must be individualized, taking into account
predisposing risk factors.
Relevant to the history is the severity and duration of
hyperbilirubinemia. Other risk factors such as prematurity,
sepsis, acidosis and Rh disease should be assessed. It is also
important to elicit a history of abnormal neonatal neurologic
signs or symptoms known to associate with ABE (abnormal
tone, abnormal cry, posturing, abnormal eye movements or
positions). Finally, later in life, one should enquire about a
history of delayed speech, gross or fine motor development,
dental enamel dysplasia of deciduous teeth or hearing abnormalities, all consistent with KSD.59
On examination, dystonia, choreoathetosis, ataxia,
variable hypo/hypertonia, spasticity, incoordination, gaze
abnormalities, staining or flaking of deciduous teeth, dental
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enamel hypoplasia, dysarthria, hearing impairment or difficulty localizing sound may be detected.59
The BIND score60 is a tool to objectify and facilitate a
clinical diagnosis of ABE as well as to monitor the neonatal
neurological exam in infants with progressive hyperbilirubinemia as a predecessor to encephalopathy. The BIND
score uses the mental state, muscle tone and cry pattern to
categorize neonates into three levels of increasing abnormality (subtle, moderate, advanced). A score ranging between
zero and three is given for each clinical parameter assessed
based on severity. A score of zero indicates a normal neonate.
A value ranging between 1 and 3 signifies subtle encephalopathy. Moderate encephalopathy and advanced encephalopathy correspond to scores of 4–6 and 7–9, respectively.
Following the publication of the classic BE facies, now
called the “kernicteric facies”63 (Figure 4), the BIND score
was modified for use primarily in low-resource settings
often without ancillary testing such as ABRs and MRIs. The
modified bilirubin-induced neurologic dysfunction scale
(M-BIND), a 12-point score, incorporates eye abnormalities
such as a divergent gaze, paralysis of upward gaze, anxious
appearance and nystagmus, and serves to better discriminate degrees of BIND severity and to aid in distinguishing
ABE from other common causes of neonatal morbidity
and mortality such as tetanus still seen in low-resources
settings.65 The reliability of using the M-BIND algorithm in
resource limited setting was assessed and was found to have
a positive predictive value of 88.9%, a negative predictive
value of 98.2% and a weighted kappa coefficient of 0.7969
(substantial agreement) between the scores obtained by the
consultants and residents.65
The tool named the brainstem auditory evoked response
(BAER), also referred to as ABR, is an effective, noninvasive screening tool with a sensitivity of 100% and
specificity of 99.7%66 in detecting hearing impairment. This
test can be used in neonates to predict impending encephalopathy, identify subtle BE that could be reversed and detect
early hearing abnormalities.67 Emerging evidence suggests
that the auditory neural pathways are the most sensitive
system to overt bilirubin toxicity, with the most consistent
feature being ANSD ± hearing loss.18,68 Thus, auditory
evaluation may improve detection of bilirubin-induced
neurotoxicity in neonates.69 The BAER recording is a series
of vertex positive waves of which wave I through wave
V are evaluated. In bilirubin neurotoxicity, the BAER is
absent or abnormal (prolonged inter-wave intervals and/or
diminished amplitudes) indicating damage to the auditory
nerve (wave l) and/or more likely auditory brainstem nuclei
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Figure 4 A baby with advanced bilirubin encephalopathy and secondary failure to thrive.
Notes: (A and B) Anxious looking, paralysis of upward gaze with lid retraction (collier sign) and facial dystonia. (C) Bicycling/windmill movement of upper limbs. (D) Neck
retraction and scissoring of lower limbs.
Note: Photographs courtesy of Dr Fatima Usman and used with maternal permission.

(waves III and V).70–73 These changes correlate significantly
with bilirubin level.70 In neonates with ANSD secondary to
ABE, abnormal BAERs with normal cochlear microphonic
(CMs) responses and initially normal otoacoustic emissions
(OAEs) are observed.61,73,75 With ANSD, OAEs, initially
normal, often disappear over time, whereas CMs never
disappear. Note that with SNHL, which is more common
than ANSD, both OAEs and CMs are abnormal or absent
to the same extent as the abnormal or absent BAER.
Similarly, cranial magnetic resonance imaging (cMRI)
can be used to detect bilirubin neurotoxicity. In ABE, MRI
may show characteristic T1-hyperintense involvement of the
globus pallidus and subthalamic nuclei, while KSD usually
demonstrates increased signal intensity on T2-weighted
images of the same regions, especially in children with
classical and motor-predominant kernicterus.68,75 Although
cMRI has an important role in the diagnosis of ABE and
KSD, it does not always correlate with clinical and laboratory findings.75 Various studies have shown inconsistent
findings in infants with bilirubin toxicity, reporting normal
cMRI results despite abnormal neurologic findings.76–78 One
should note that it is easy to confuse a benign appearance of
high T1 signal intensity in the basal ganglia of newborn and
premature infants as a result of incomplete myelination.75
This point serves to emphasize the importance of relying
on the expertise of a radiologist well versed in MRI of the
newborn infant and of not relying on a single test to make a
diagnosis of ABE.
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Based on the presence of abnormal neurologic findings,
BAER and cMRI, Shapiro proposed the use of the terms
“certain”, “probable” and “possible” to define neonates with
KSD.16 In the recent paper by Le Pichon et al,15 he further
clarified these terms and further encourages using two Kernicterus Diagnostic Toolkits to help make a diagnosis of KSD
in infants born at or near term. These toolkits are designed to
be used by health care professionals, caregivers and families
to assess the probability, severity and type of a KSD. Each
toolkit is scored and provides a quantifiable measure that can
be comparable across assessors. The authors propose validating the toolkits in hopes that a standard diagnostic algorithm
for KSDs will be useful to families, providers and researchers.

Acute encephalopathy progressing
to KSD
A considerable amount of research has focused on how best
to predict the likelihood of bilirubin neurotoxicity, but to date
no study has identified a direct causal factor as an absolute
predictor of ABE with subsequent progression to KSD.79
Kaplan and Hammerman reported ABE progression to KSD
in 84% of affected infants.61 There have been several reports
of resolution of ABE without progression to KSD in infants
with moderate to severe disease following treatment.80
Observational literature supports the assertion that
genetic factors are relevant modulators to bilirubin neurotoxicity in addition to previously described modifiers such
as prematurity, high levels of bilirubin with long duration of
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exposure, presence of comorbid conditions that predispose
to hemolysis and increase propensity for injury, factors that
alter BBB permeability to bilirubin, and variations in albumin concentration and/or its bilirubin-binding capacity.14,47,81
There is persuasive theoretic evidence backing variable gene
expression as a significant determinant for bilirubin susceptibility and subsequent progression to KSD. It is likely that
regional differential genetic expression accounts, at least in
part, for the selective brain vulnerability. While there have
been numerous genes linked to the development of hyperbilirubinemia, relatively few studies have reported on the
genes and pathways important to determine the newborn’s
susceptibility to the toxic effect of bilirubin. Additionally, it
is well recognized that the precise level at which bilirubin is
neurotoxic is unpredictable.18,82–84 It is therefore reasonable
to postulate that a complex nature-nurture interplay underlies
the mechanisms predisposing individuals to ABE and KSD.
Several lines of evidence point toward environmental
factors as significant risks to disease progression. Delayed
feeding, use of icterogenic substances, delay in seeking
timely and appropriate care including failed recognition of
the onset of severe hyperbilirubinemia and poor perception
of its severity have been linked with advancing disease.59,68
Conversely, prompt and aggressive treatment with exchange
blood transfusion and adjunct intensive phototherapy reverses
neurotoxicity largely by reducing the duration of exposure of
brain cells to UB.85–87 Reversal of abnormal ABR has been
reported following exchange blood transfusion,86,87 supporting the recommendation to treat aggressively infants with
moderate to advanced ABE, even when the TSB is below the
threshold for exchange transfusion.14 Another potentiating
factor in disease progression is the clinical stage of disease
at presentation. Infants presenting with mild disease are
more likely to have complete reversal of neuronal injury with
aggressive treatment.87 Phase 1 ABE is reversible with prompt
and appropriate treatment, while the outcome in phase 2 is
variable.60 Individualized and timely intervention may prevent
further brain damage and minimize the severity of the sequelae
in the advanced phase of the disease.60 One might summarize
this entire discussion by stating the following: the faster and
the more aggressive the treatment, the less the likelihood of
progression and the better the outcome. As such, treatment
should not be withheld in any infant due to late presentation.

Prevention of ABE and KSD
An anticipatory and individualized approach with the goal
of avoiding excessive hyperbilirubinemia is the key to preventing severe neonatal jaundice, ABE87 and its subsequent
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progression to KSD. Using a systematic tiered approach,
targeted preventive strategies are essential at each level
during the assessment of newborn infants to prevent these
complications. Obstacles to preventive strategies and need
for solutions to overcome obstacles at each point have been
elucidated in manuscripts such as the ones by Olusanya et al91
and Ogunfowora and Daniel.89 At the primary level, programs aimed at promoting and supporting successful breast
feeding, documentation of the mother’s blood group during
antenatal care with cheap and available and appropriately
used Rhesus immunoglobulin (Rhogam™), meticulous risk
assessment and providing the parents with written and oral
information about jaundice are paramount.90 Included in this
counseling must be advice to avoid products such as camphor,
henna, naphthalene and mentholatum in neonatal care.91
Data presented at a recent scientific meeting highlighted a
significant reduction in ABE with maternal education alone.92
Similarly, recognizing that visual estimation of the severity
of jaundice may be misleading93 and establishing protocols
for the identification and evaluation of hyperbilirubinemia
are of prime importance. Improvement on older screening
methods are needed and being effectively pursued. It is
essential to screen for jaundice and G6PD deficiency as part
of a systemic evaluation on all babies for the risk of severe
hyperbilirubinemia before discharge.14,96 A shortened hospital
stay of <48 hours after delivery especially for preterm babies
should be discouraged.14 Regardless of the place of birth or
duration of hospitalization, infants should be screened by the
most reliable method available around day 3–4 of life and
of course sooner if jaundice in the first 24 hours of life or
jaundice of the eyes, hands or feet is diagnosed.14
At the secondary level, measuring bilirubin levels (TSB
or TcB) in jaundiced babies, interpreting all bilirubin levels
based on hour-specific modified country-specific Bhutanitype nomogram is advocated.95 Additionally, providing
appropriately timed and effective treatment using gestational
age, weight appropriate threshold for risk assessment and
country-specific guidelines is urgently needed.14,91 Effective
treatment means a minimum conventional phototherapy
with an irradiance of at least 10-W/nm/cm2 but preferably
intensive at 30-W/nm/cm2 or greater for those with serious
hyperbilirubinemia including need for exchange transfusion
and ABE.14,91 With appropriate studies and location-specific
protocols, newer solutions providing effective phototherapy
should be considered such as filtered sunlight phototherapy
using selectively tested window tinting and/or solar and/
or battery powered units should be considered in locations
without consistent electricity.91,96 Combined with effective
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phototherapy, health care facilities also need to be able to
quickly refer to tertiary centers that are able to do emergent
exchange blood transfusions when needed.87,88 Finally, close
post-discharge follow-up strategies are critical in preventing
bilirubin neurotoxicity.88

Follow-up
Those who unfortunately fall through the cracks in our health
care systems and develop KSD need to have appropriate
rehabilitation services provided. Limitation of disabilities
and rehabilitation of survivors is multi-disciplinary and
determined by disease severity. The use of cued speech,
hearing aids and cochlear implants for those with hearing
impairment and physical and occupational therapy with
or without pharmacotherapy (trihexyphenidyl, baclofen,
benzodiazepines and botulinum toxin injections) for motor
involvement may be helpful. Deep brain stimulation may
be beneficial in some cases.15 Unfortunately, most of these
options are priced out of the range of infants and children in
LMICs. Our goal, however, should be to bring these therapies
to those who need them the most regardless of their country
or socioeconomic status maximizing the potential of these
vulnerable infants to maximize their potential as the grow
and develop.

Conclusion
The relationship between ABE and subsequent development
of KSD has always been an area of controversy, especially
when determining the risk of progression. Indeed, except
for the advanced stage of ABE, other stages do not connote
the development of KSD. In order to predict this risk of
progression, appropriate epidemiologic studies to document
the incidence of KSD using precise indicators of long-term
neurodevelopmental outcome as well as comparing predisposing factors are necessary.
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